Guardant Health, Inc. (NASDAQ:GH – Get Free Report) Director Alex Azar II sold 69 shares of Guardant Health stock in a transaction that occurred on Monday, November 16th. The stock was sold at an average price of $149.56, for a total value of $10,319.64. Following the completion of the sale, the director owned 962 shares of the company’s stock, valued at approximately $143,876.72. The trade was a 6.69% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Guardant Health Stock Performance
Shares of GH opened at $143.28 on Wednesday. The firm has a market cap of $19.38 billion, a PE ratio of -38.93 and a beta of 1.67. Guardant Health, Inc. has a 52-week low of $74.55 and a 52-week high of $191.05. The business’s 50 day moving average price is $167.94 and its two-hundred day moving average price is $133.33.
Guardant Health (NASDAQ:GH – Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.46. The company had revenue of $360.98 million for the quarter, compared to analyst estimates of $350.72 million. The business’s quarterly revenue was up 36.1% compared to the same quarter last year. During the same period last year, the business earned ($0.74) EPS. Research analysts predict that Guardant Health, Inc. will post -3.08 EPS for the current fiscal year.
Analyst Ratings Changes
GH has been the topic of several research analyst reports. Morgan Stanley increased their target price on shares of Guardant Health from $185.00 to $200.00 and gave the stock an “overweight” rating in a research note on Monday, October 12th. BTIG Research lifted their price target on shares of Guardant Health from $195.00 to $210.00 and gave the company a “buy” rating in a research note on Tuesday, October 27th. UBS Group upped their price objective on shares of Guardant Health from $175.00 to $225.00 and gave the company a “buy” rating in a report on Wednesday, September 9th. Rothschild & Co Redburn began coverage on shares of Guardant Health in a report on Tuesday, September 8th. They set a “buy” rating and a $203.00 price objective on the stock. Finally, Mizuho increased their price objective on shares of Guardant Health from $175.00 to $200.00 and gave the stock an “outperform” rating in a research report on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $190.88.
View Our Latest Research Report on GH
Institutional Investors Weigh In On Guardant Health
Hedge funds and other institutional investors have recently modified their holdings of the company. Allworth Financial LP grew its holdings in Guardant Health by 38.6% during the third quarter. Allworth Financial LP now owns 1,486 shares of the company’s stock worth $265,000 after buying an additional 414 shares in the last quarter. PointState Capital LP purchased a new stake in Guardant Health in the 3rd quarter valued at $176,851,000. Balance Capital Partners L.P. purchased a new stake in Guardant Health in the 3rd quarter valued at $3,746,000. Lighthouse Investment Partners LLC purchased a new stake in Guardant Health in the 3rd quarter valued at $2,548,000. Finally, Worldquant Millennium Advisors LLC bought a new position in Guardant Health during the 3rd quarter valued at $4,982,000. Institutional investors own 92.60% of the company’s stock.
About Guardant Health
Guardant Health is a precision oncology company that develops blood- and tissue-based tests to help guide cancer care. Founded in 2012 by Helmy Eltoukhy and AmirAli Talasaz, the company focuses on using genomic information to support cancer detection, treatment selection and disease monitoring. Its products include Guardant360 tests, which analyze tumor-related genetic changes to help inform treatment decisions, and Guardant Reveal, which is designed to detect residual or recurring cancer after treatment.
Featured Articles
- Five stocks we like better than Guardant Health
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.
